載入...
Somatostatin receptor radionuclide therapy in neuroendocrine tumors
Peptide receptor radionuclide therapy (PRRT) using (177)Lu-DOTATATE has been approved for the treatment of gastroenteropancreatic NETs. An understanding of benefits and risks is important for the appropriate implementation of this therapy. This review summarizes study data supporting the use of radi...
Na minha lista:
| 發表在: | Endocr Relat Cancer |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8118168/ https://ncbi.nlm.nih.gov/pubmed/33608483 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-20-0360 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|